Celyad Oncology (XBRU:CYAD) Total Liabilities : €11.16 Mil (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Total Liabilities?

Celyad Oncology's Total Liabilities for the quarter that ended in Jun. 2023 was €11.16 Mil.

Celyad Oncology's quarterly Total Liabilities declined from Jun. 2022 (€32.49 Mil) to Dec. 2022 (€15.40 Mil) and declined from Dec. 2022 (€15.40 Mil) to Jun. 2023 (€11.16 Mil).

Celyad Oncology's annual Total Liabilities increased from Dec. 2020 (€35.09 Mil) to Dec. 2021 (€36.30 Mil) but then declined from Dec. 2021 (€36.30 Mil) to Dec. 2022 (€15.40 Mil).

Celyad Oncology Total Liabilities Historical Data

The historical data trend for Celyad Oncology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Total Liabilities Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

38.71

44.22

35.09

36.30

15.40

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial															36.30	32.72	32.49	15.40	11.16

Celyad Oncology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Celyad Oncology's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	10.426	+	(0.118	+	0.258
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	4.584	+	0.013)
	=	15.40

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	19.716	-	4.317
	=	15.40

Celyad Oncology's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.092	+	(0.351	+	0.217
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	4.486	+	0.013)
	=	11.16

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	12.178	-	1.019
	=	11.16

Celyad Oncology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (XBRU:CYAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

1C0:Germany

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines